A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 10, 2008, Pages 1202-1211

  Matsueda, Kei ^a   Harasawa, Shigeru ^b   Hongo, Michio ^c   Hiwatashi, Nobuo ^d   Sasaki, Daisuke ^e  

^a 1 7 1 Kohnodai   (Japan)

^b Saiseikai Kawaguchi General Hospital   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d Iwaki Kyoritsu Gen Hosp   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

Author keywords

5 HT3 receptor antagonist; Irritable bowel syndrome; Ramosetron; Randomized controlled study

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; RAMOSETRON;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION URGENCY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES ANALYSIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HARD FECES; HUMAN; IRRITABLE COLON; JAPANESE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; BENZIMIDAZOLES; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; JAPAN; MALE; MIDDLE AGED; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 52149088774     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802240255     Document Type: Article

References (35)

1. Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 1999;13:371-84.
2. Kumano H, Kaiya H, Yoshiuchi K, Yamanaka G, Sasaki T, Kuboki T. Comorbidity of irritable bowel syndrome, panic disorder, and agoraphobia in a Japanese representative sample. Am J Gastroenterology 2004;99:370-6.
3. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60.
4. Camilleri M, Heading RC, Thompson WG. Consensus reports: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1407-30.
5. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42(6):845-9.
6. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganiere M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002;122:1771-7.
7. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999;13 Suppl 2:15-30.
8. 3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999;13 Suppl 2:31-8.
9. Olden KW. Irritable bowel syndrome: An overview of diagnosis and pharmacologic treatment. Cleve Clin J Med 2003;70 Suppl 2:S3-7.
10. 3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59.
11. Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40.
12. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet 2000;355:1035-40.
13. Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterology 2001;96:2662-70.
14. Jones RH, Holtmann G, Rodrigo L, Ensanullah RSB, Crompton PM, Jacques LA, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999;13:1419-27.
15. Miyata K, Kamato T, Nishida A, Katsuyama Y, Iwai A, Yuki H, et al. Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7- tetrahydro-1H- benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine 3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther 1991;259:15-21.
16. 3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc) 2002;38:75-89.
17. Miyata K, Kamato T, Nishida A, Ito H, Yuki H, Yamamo M, et al. Role of the serotonin 3 receptor in stress-induced defecation. J Pharmacol Exp Ther 1992;261:297-303.
18. 3 receptor in CRH-induced defecation in rats. Am J Physiol 1998;274:G827-31.
19. Hirata T, Keto Y, Funatsu T, Sasamata M, Miyata K. Effects of ramosetron hydrochloride on defecation and abdominal pain in rats. Gastroenterology 2005;128 Suppl 2:A466.
20. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A Phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Under review.
21. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007;5:534-40.
22. Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology 2002;123:1686-701.
23. Whitehead WE, Cheskin LJ, Heller BR, Robinson JC, Crowell MD, Benjamin C, et al. Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology 1990;98:1485-9.
24. Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002;50:471-4.
25. Naliboff BD, Berman S, Chang L, Derbyshire SWG, Suyenobu B, Vogt BA, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003;124:1738-47.
26. US Food and Drug Administration Center for Drug Evaluation and Research, Lotronex Pharmacology Review( s), http:: //www.fda.gov/cder/foi/nda/2000/ 21107a_Lotronex.htm
27. Berman S, Munakata J, Naliboff BD, Chang L, Mandelkern M, Silverman D, et al. Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain 2000;4:157-72.
28. 3 receptor antagonist alosetron. Gastroenterology 2002;123:969-77.
29. Mawe GM, Coates MD, Moses PL. intestinal serotonin signalling in irritable bowel syndrome [review article]. Aliment Pharmacol Ther 2006;23:1067-76.
30. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657-64.
31. Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004;53:1452-8.
32. Camilleri M. Is there a SERT-a in association with IBS? Gut 2004;53:1396-9.
33. Tally NJ, Zinsmeister AR, Melton LJ III. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995;142:76-83.
34. Lotronex® tablets (prescribing information/product label).
35. Suh DC, Kahler KH, Choi IS, Shin H, Kralstein J, Shetzline M. Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis. Aliment Pharmacol Ther 2007;25:681-92.